



True precision medicine through single-cell science


- Best-in-class single-cell biomarker discovery algorithm
- *In vitro* diagnostic asset in development - women's health
- Completed first closing of Series A financing round



Key achievement

3 new patents filed on the discoveries

- **Successful first closing of the series A financing round**
Use of funds:
 - IVD development endometriosis
 - develop industry partnerships to monetize the discovery platform ScaiVision
- **Appointed a new Chief Operating Officer with executive pharma background, Corinne Solier, as well as a new board member, Anna Sumeray**
- **Established an ISO:9001-compliant QMS system**
- **Ongoing project for a cell therapy company, involving the analysis of their proprietary single-cell data**
- **Validation of a blood-based biomarker in endometriosis shows >95% specificity**



Outlook for H1-2022

- Multiple service-deals with biotech in place
- Validation of endometriosis biomarker candidates & kick-off of assay development

Second closing of series A planned in H1-2022

[Get in touch with us!](#)



www.scailyte.com
[Dr. Peter Nestorov](#)
CEO & Co-founder



True precision medicine through single-cell science

- Best-in-class single-cell biomarker discovery algorithm
- *In vitro* diagnostic asset in development - women's health
- Completed first closing of Series A financing round



QUOTE

Corinne Solier, PhD

Chief Operating Officer at Scailyte
Head of ScaiVision Services BU



“ The next revolution will be realized when we can fully harness the power of single cell biological information to discover new and more sensitive biomarkers of diagnostic, predictive and prognostic value for individual patients. Scailyte’s perfectly suited capabilities as well as the passionate and excellent team convinced me to join the company, to fulfill our mission of advancing precision medicine. ”

Profile

Pharma executive with over 15 years of experience advancing precision medicine through efforts tailored to optimize the benefit:risk ratio of new medicines. Held global responsibilities leading clinical protein biomarker area, headed the department of 120 scientists.

QUOTE

“ The Scailyte platform operates at the exciting interface of AI and Precision Medicine, and has a broad applicability across multiple therapeutic areas. There are so many possibilities to drive more targeted drug development and I am excited to work with the rest of the Board to help the company make the smartest strategic choices. I hope I can also connect Scailyte with partner companies and investors to help them leverage the value of their innovation. ”

Profile

Global Biotech executive and entrepreneur with broad experience of defining and building successful businesses. Advisor and investor in biotech start-ups, pioneer and general manager of European launch projects and experienced business development leader and negotiator.

Anna Sumeray

Biotech startup CEO, member of the Scailyte Board of Directors



www.scailyte.com
[Dr. Peter Nestorov](#)
CEO & Co-founder